[go: up one dir, main page]

DE69429260D1 - Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie - Google Patents

Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie

Info

Publication number
DE69429260D1
DE69429260D1 DE69429260T DE69429260T DE69429260D1 DE 69429260 D1 DE69429260 D1 DE 69429260D1 DE 69429260 T DE69429260 T DE 69429260T DE 69429260 T DE69429260 T DE 69429260T DE 69429260 D1 DE69429260 D1 DE 69429260D1
Authority
DE
Germany
Prior art keywords
animal origin
gene therapy
adenoviral vectors
therapeutic
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69429260T
Other languages
English (en)
Other versions
DE69429260T2 (de
DE69429260T3 (de
Inventor
Hedi Haddada
Bernard Klonjkowski
Michel Perricaudet
Emmanuelle Vigne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTELION, VITRY SUR SEINE, FR
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9447235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69429260(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of DE69429260D1 publication Critical patent/DE69429260D1/de
Publication of DE69429260T2 publication Critical patent/DE69429260T2/de
Publication of DE69429260T3 publication Critical patent/DE69429260T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69429260T 1993-05-18 1994-05-06 Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie Expired - Lifetime DE69429260T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9305954 1993-05-18
FR9305954A FR2705361B1 (fr) 1993-05-18 1993-05-18 Vecteurs viraux et utilisation en thérapie génique.
PCT/FR1994/000531 WO1994026914A1 (fr) 1993-05-18 1994-05-06 Vecteurs adenoviraux d'origine animale et utilisation en therapie genique

Publications (3)

Publication Number Publication Date
DE69429260D1 true DE69429260D1 (de) 2002-01-10
DE69429260T2 DE69429260T2 (de) 2002-07-04
DE69429260T3 DE69429260T3 (de) 2006-08-03

Family

ID=9447235

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69429260T Expired - Lifetime DE69429260T3 (de) 1993-05-18 1994-05-06 Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie

Country Status (26)

Country Link
US (1) US6294377B1 (de)
EP (1) EP0698108B2 (de)
JP (2) JP3995259B2 (de)
KR (1) KR100379569B1 (de)
CN (1) CN1067722C (de)
AT (1) ATE209686T1 (de)
AU (1) AU696495B2 (de)
BR (1) BR9406720A (de)
CA (1) CA2163256C (de)
CZ (1) CZ284903B6 (de)
DE (1) DE69429260T3 (de)
DK (1) DK0698108T4 (de)
ES (1) ES2167365T5 (de)
FI (1) FI118538B (de)
FR (1) FR2705361B1 (de)
HU (1) HU221340B1 (de)
IL (1) IL109644A (de)
NO (1) NO320818B1 (de)
NZ (1) NZ266475A (de)
PL (1) PL182814B1 (de)
PT (1) PT698108E (de)
RU (1) RU2233333C2 (de)
SK (1) SK282354B6 (de)
UA (1) UA66417C2 (de)
WO (1) WO1994026914A1 (de)
ZA (1) ZA943358B (de)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU663702B2 (en) 1991-03-06 1995-10-19 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
IL113052A0 (en) 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
EP0784690B1 (de) 1994-06-10 2006-08-16 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
FR2722507B1 (fr) * 1994-07-12 1996-08-14 Rhone Poulenc Rorer Sa Adenovirus comportant un gene codant pour une no synthase
FR2724320B1 (fr) * 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
EA001616B1 (ru) 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
FR2731710B1 (fr) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
FR2732357B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6019978A (en) * 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
US5698202A (en) * 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
FR2740344B1 (fr) * 1995-10-31 1997-11-21 Rhone Poulenc Rorer Sa Application de la proteine gax au traitement de cancers
JP2002512501A (ja) * 1996-07-03 2002-04-23 メリアル インコーポレイテッド 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ）
WO1998010087A1 (en) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
CA2288306A1 (en) 1997-04-28 1998-11-05 Rhone-Poulenc Rorer S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
EP2386630A1 (de) 1997-10-14 2011-11-16 Darwin Molecular Corporation Thymidinkinasemutanten und Fusionsproteine mit Thymidinkinase- und Guanylatkinaseaktivität
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
US6653088B1 (en) 1997-10-24 2003-11-25 Aventis Pharma S.A. Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide
ES2247780T3 (es) 1998-01-08 2006-03-01 Aventis Pharmaceuticals Inc. Un conejo transgenico que expresa una lipoproteina (a) humana funcional.
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
US6506889B1 (en) 1998-05-19 2003-01-14 University Technology Corporation Ras suppressor SUR-8 and related compositions and methods
CA2339409A1 (en) 1998-08-11 2000-02-24 Darwin Discovery Ltd. Identification of the gene causing the mouse scurfy phenotype and its human ortholog
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ATE481487T1 (de) 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US7063850B1 (en) 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US6441156B1 (en) * 1998-12-30 2002-08-27 The United States Of America As Represented By The Department Of Health And Human Services Calcium channel compositions and methods of use thereof
FR2794771B1 (fr) * 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
CA2395839A1 (en) 1999-12-27 2001-07-05 The Regents Of The University Of California Gene therapy for congestive heart failure
HUP0203863A3 (en) 2000-01-12 2008-03-28 Univ Yale Nogo receptor-mediated blockade of axonal growth
ATE374597T1 (de) 2000-03-24 2007-10-15 Biosphere Medical Inc Mikrokugeln zur aktiven embolisierung
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
US7060442B2 (en) 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
MXPA03005386A (es) 2000-12-28 2004-04-20 Wyeth Corp Proteina protectora recombinante de streptococcus pneumoniae.
WO2002090600A2 (en) 2001-05-08 2002-11-14 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein
AUPR518501A0 (en) 2001-05-22 2001-06-14 Unisearch Limited Yin yang-1
WO2003004088A2 (en) 2001-07-05 2003-01-16 Aventis Pharma S.A. Method of administration of a gene of interest to the heart and vasculature
US7108975B2 (en) 2001-09-21 2006-09-19 Regents Of The University Of Michigan Atlastin
US7582425B2 (en) 2001-09-21 2009-09-01 The Regents Of The University Of Michigan Atlastin
US20040023910A1 (en) * 2001-09-28 2004-02-05 Zhiming Zhang Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
MXPA04003852A (es) 2001-10-26 2005-02-17 Univ Tennessee Res Foundation Composiciones de vacuna estreptococica multivalente, y metodos para sus uso.
EP1453537A1 (de) 2001-12-12 2004-09-08 FH Faulding & Co. Limited Zusammensetzung zur konserverierung von viren
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
CN100422316C (zh) 2002-05-24 2008-10-01 先灵公司 抗胰岛素样生长因子受体(igfr)的人源中和抗体
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
FR2845395B1 (fr) * 2002-10-08 2008-05-30 Agronomique Inst Nat Rech Vecteurs adenoviraux recombinants et leurs applications
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
US7432057B2 (en) 2004-01-30 2008-10-07 Michigan State University Genetic test for PSE-susceptible turkeys
CA2836987C (en) 2004-05-26 2016-07-05 Psioxus Therapeutics Limited Chimeric adenoviruses for use in cancer treatment
US7604798B2 (en) 2004-07-15 2009-10-20 Northwestern University Methods and compositions for importing nucleic acids into cell nuclei
ATE527281T1 (de) 2004-07-16 2011-10-15 Us Gov Health & Human Serv Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
EP3002330A1 (de) 2005-05-27 2016-04-06 Ospedale San Raffaele S.r.l. Genvektor
CA2643732C (en) 2006-02-27 2012-08-21 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
CN101495633B (zh) 2006-07-28 2015-01-07 塞诺菲-安万特股份有限公司 用于治疗肿瘤的组合物和方法
EP2829551B1 (de) 2006-10-19 2017-12-13 CSL Limited Hochaffine Antikörperantagonisten des Interleukin-13-Rezeptors Alpha 1
ES2388567T3 (es) 2006-10-19 2012-10-16 Csl Limited Anticuerpos anti-il-13r alfa 1 y usos de los mismos
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2231164A1 (de) 2007-12-03 2010-09-29 The Regents of the University of California Oxysterole zur aktivierung von hedgehog-signalisierung, osteoinduktion, antiadipogenese und wnt-signalisierung
DK2356135T3 (en) 2008-11-05 2017-12-04 Wyeth Llc IMMUNOGEN MULTICOMPONENT COMPOSITION FOR THE PREVENTION OF BETA-HAEMOLYTIC STRUCTURAL TOC (BHS) DISEASE
US20110293608A1 (en) 2008-12-03 2011-12-01 The Johns Hopkins Univeristy Annexin a2 as immunological target
ES2629630T3 (es) * 2008-12-04 2017-08-11 Curna, Inc. Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
AU2011227050B2 (en) 2010-03-19 2016-12-08 University Of South Alabama Methods and compositions for the treatment of cancer
ES2664572T3 (es) * 2010-05-26 2018-04-20 Curna, Inc. Tratamiento de enfermedades relacionadas con el homólogo atonal 1 (ATOH1) mediante inhibición del transcrito antisentido natural a ATOH1
ES2863526T3 (es) * 2010-06-23 2021-10-11 Curna Inc Tratamiento de enfermedades relacionadas con la subunidad alfa del canal de sodio (SCNA), controlado por voltaje, mediante inhibición de la transcripción antisentido natural a SCNA
PL3831406T3 (pl) 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
JP5976652B2 (ja) 2010-09-10 2016-08-24 ワイス・エルエルシー 髄膜炎菌ｏｒｆ２０８６抗原の非脂質化変異体
US9458456B2 (en) 2011-04-01 2016-10-04 University Of South Alabama Methods and compositions for the diagnosis, classification, and treatment of cancer
US9464291B2 (en) 2012-01-06 2016-10-11 University Of South Alabama Methods and compositions for the treatment of cancer
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR101763625B1 (ko) 2012-03-09 2017-08-01 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
JP6262723B2 (ja) 2012-05-07 2018-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ オキシステロールアナログｏｘｙ１３３は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
WO2014113436A1 (en) * 2013-01-15 2014-07-24 The Regents Of The University Of California Adenoviruses and their use
EP2964665B1 (de) 2013-03-08 2018-08-01 Pfizer Inc Immunogene fusionspolypeptide
US10981961B2 (en) 2013-03-11 2021-04-20 University Of Florida Research Foundation, Incorporated Delivery of card protein as therapy for occular inflammation
WO2014179756A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
KR101905278B1 (ko) 2013-09-08 2018-10-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
SI3021859T1 (en) 2013-10-25 2018-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses equipped with heterologous genes
WO2015127094A1 (en) 2014-02-19 2015-08-27 University Of Florida Research Foundation, Inc. Delivery of nrf2 as therapy for protection against reactive oxygen species
BR122020020864B1 (pt) * 2014-06-17 2022-06-21 National Center Of Neurology And Psychiatry Oligômero antissentido, composição farmacêutica e uso de um oligômero antissentido ou um sal ou hidrato farmaceuticamente aceitável do mesmo
HK1244299A1 (zh) 2014-11-14 2018-08-03 Voyager Therapeutics, Inc. 治療肌萎縮側索硬化(als)的組合物和方法
CA2975447C (en) 2015-01-30 2021-02-23 The Regents Of The University Of California Spinal subpial gene delivery system
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
RS60105B1 (sr) 2015-04-30 2020-05-29 Psioxus Therapeutics Ltd Onkološki adenovirus kodiran proteinom b7
JP7572700B2 (ja) 2015-10-19 2024-10-24 ユニバーシティ オブ メリーランド ボルチモア 改変ヒト初代血液樹状細胞株を生成するための方法
WO2017103291A1 (en) 2015-12-17 2017-06-22 Psioxus Therapeutics Limited Virus encoding an anti-tcr-complex antibody or fragment
EP3436427B1 (de) 2016-03-28 2021-12-08 The Regents of the University of California Verfahren und zusammensetzung zur behandlung von neuronaler hypererregbarkeit
US11560412B2 (en) 2016-04-01 2023-01-24 University Of Maryland, Baltimore Compositions comprising GRIM-19 therapeutics and methods of use
DK3445406T3 (da) 2016-04-20 2021-08-30 Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P Sammensætninger og fremgangsmåder til forøget genekspression af pklr
MX2019002328A (es) 2016-08-29 2019-07-04 Psioxus Therapeutics Ltd Adenovirus armado con captador biespecífico de linfocitos t (bite).
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
UY37406A (es) 2016-09-20 2018-03-23 Boehringer Ingelheim Vetmedica Gmbh Nuevo sitio de inserción orf70 de ehv
MY199929A (en) 2016-09-20 2023-11-29 Boehringer Ingelheim Vetmedica Gmbh Canine adenovirus vectors
CN110072546B (zh) 2016-09-20 2023-10-31 勃林格殷格翰动物保健有限公司 新的猪流感疫苗
BR112019005418A2 (pt) 2016-09-20 2019-10-01 Boehringer Ingelheim Vetmedica Gmbh novos promotores
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112020007444A2 (pt) 2017-10-16 2020-10-20 Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. vetores lentivirais para a liberação de pklr para tratar deficiência de piruvato quinase
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
WO2020010035A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Cannula system
JP7565218B2 (ja) 2018-07-02 2024-10-10 ボイジャー セラピューティクス インコーポレイテッド 筋萎縮性側索硬化症および脊髄に関連する障害の治療
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
CA3185267A1 (en) 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector
WO2022232375A1 (en) 2021-04-30 2022-11-03 Kalivir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
AU2022368907A1 (en) 2021-10-20 2024-05-02 University Of Copenhagen Rejuvenation treatment of age-related white matter loss
JP2024542015A (ja) 2021-11-02 2024-11-13 ユニバーシティ オブ ロチェスター 脳内でのｔｃｆ７ｌ２媒介性髄鞘再生
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
WO2024163747A2 (en) 2023-02-02 2024-08-08 University Of Rochester Competitive replacement of glial cells
WO2025090427A1 (en) 2023-10-23 2025-05-01 University Of Rochester Glial-targeted relief of hyperexcitability in neurodegenerative diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
GB9001766D0 (en) * 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU670933B2 (en) * 1992-03-27 1996-08-08 Collimore Enterprises Pty Ltd Formwork device

Also Published As

Publication number Publication date
CN1067722C (zh) 2001-06-27
EP0698108A1 (de) 1996-02-28
PL182814B1 (pl) 2002-03-29
NZ266475A (en) 2000-04-28
BR9406720A (pt) 1996-02-06
NO954466D0 (no) 1995-11-07
CZ302895A3 (en) 1996-02-14
DK0698108T4 (da) 2006-04-18
KR100379569B1 (ko) 2004-03-06
FI955552A0 (fi) 1995-11-17
DK0698108T3 (da) 2002-02-11
FI955552L (fi) 1995-12-27
AU696495B2 (en) 1998-09-10
JP2004180689A (ja) 2004-07-02
DE69429260T2 (de) 2002-07-04
EP0698108B1 (de) 2001-11-28
RU2233333C2 (ru) 2004-07-27
JP3995259B2 (ja) 2007-10-24
DE69429260T3 (de) 2006-08-03
UA66417C2 (en) 2004-05-17
ATE209686T1 (de) 2001-12-15
IL109644A (en) 2005-06-19
ZA943358B (en) 1995-01-16
US6294377B1 (en) 2001-09-25
FR2705361A1 (fr) 1994-11-25
HUT73465A (en) 1996-08-28
SK144795A3 (en) 1996-04-03
ES2167365T3 (es) 2002-05-16
EP0698108B2 (de) 2005-12-21
HU221340B1 (en) 2002-09-28
FI118538B (fi) 2007-12-14
PL311660A1 (en) 1996-03-04
CZ284903B6 (cs) 1999-04-14
KR960702525A (ko) 1996-04-27
AU6787894A (en) 1994-12-12
HU9503297D0 (en) 1996-01-29
CA2163256C (fr) 2008-09-23
PT698108E (pt) 2002-04-29
CA2163256A1 (fr) 1994-11-24
ES2167365T5 (es) 2006-08-16
NO320818B1 (no) 2006-01-30
CN1124040A (zh) 1996-06-05
SK282354B6 (sk) 2002-01-07
NO954466L (no) 1995-11-07
JPH08510122A (ja) 1996-10-29
WO1994026914A1 (fr) 1994-11-24
FR2705361B1 (fr) 1995-08-04
IL109644A0 (en) 1994-08-26

Similar Documents

Publication Publication Date Title
DE69429260D1 (de) Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie
DE69630890D1 (de) Peptid-immitierende substanzen in der krebstherapie
DE69434447D1 (de) Für die gentherapie verwendbare plasmide
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
DE69830087D1 (de) Gerät zur therapeutischen Kauterisation von vorbestimmten Volumen biologischen Gewebes
DE69840952D1 (de) Gerät zur kontrollierten Abgabe von pharmazeutischen und medizinischen Produkten
HUP9902867A3 (en) Therapeutic use of vegf protein or nucleic acid coding same and implant, especially for the treatment of intimal hyperplasia
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
DE69431046D1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
WO2000065028A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
IL128569A0 (en) Fibroblast growth factor homologous factor S(FHFs) and methods of use
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
ATE428438T1 (de) Tcf-ii enthaltende medizinische zusammensetzung
DE69718047D1 (de) Therapeutische verwendung von bpi proteineprodukten bei patienten mit zystischer fibrose
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
NZ336371A (en) Human gene therapy using DNA/RNA cassette expression systems

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: CENTELION, VITRY SUR SEINE, FR

8366 Restricted maintained after opposition proceedings
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC